Head-to-head evidence
Linagliptin vs SYR-472
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Linagliptin · Tradjenta
Marketed by Boehringer Ingelheim and partners
NCT00602472 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.
SYR-472
Developed by Takeda Pharmaceutical Company
NCT02324569 · Phase 3 · completed
The 12-week comparison randomized 240 participants and used quadruple blinding with placebo control. The primary HbA1c endpoint was met, with a statistically significant treatment difference, but HbA1c is a surrogate laboratory measure rather than a hard clinical endpoint; the subsequent long-term period was open-label.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Linagliptin's landscape · SYR-472's landscape